Roche Launches Next-Generation Targeted Sequencing Portfolio, Redefining Standards in Precision and Efficiency

Roche Diagnostics Announces the Launch of Its Newly Upgraded Targeted Sequencing Product PortfolioRecently, Roche Diagnostics announced that its newly upgraded targeted sequencing product portfolio is now commercially available. This upgrade encompasses the entire workflow—from probe manufacturing processes and probe algorithm design to the overall targeted sequencing procedure—while supporting both manual and automated operations. It provides users with a convenient, reliable, and efficient solution for targeted sequencing sample preparation, along with comprehensive one-stop technical support and services.With the launch of Roche’s new product portfolio, the potential of targeted sequencing in clinical research will be further unlocked, injecting new momentum into technological innovation and industry development.

Achieving high-quality experimental data while effectively reducing sequencing costs relies on advanced probe technology. The probes have been upgraded to high-fidelity probes and undergone rigorous NGS QC to ensure efficient capture of target regions, thereby delivering high-quality and stable sequencing results.

From the data performance perspective,Uniformity Significantly Improved, eliminating the need to increase sequencing data volume to compensate for regions with insufficient depth, thereby significantly reducing sequencing costs; compared to previous probe versions,Further Reduction in PCR Duplication Rate (PCR Duplicates), thereby increasing the proportion of valid data. Meanwhile, high-fidelity probes will enhance the reliability of variant detection, improving the accuracy of clinical research.

For whole-exome sequencing, a commonly used approach in research, Roche’s KAPA HyperExome probe captures a 43 Mb region, covering the latest pathogenic and likely pathogenic genes from databases such as CCDS, RefSeq, Ensembl, GENCODE, and ClinVar, as well as well-annotated non-coding regions. After multiple optimizations, it provides researchers with high-quality data support. More uniquely,This exon design also includes 387 SNP loci for sample tracking., unlike manual labeling, these SNP loci constitute sample identification IDs derived from the DNA itself, enabling clear tracking of each sample throughout the testing process and monitoring for cross-sample contamination, thereby effectively preventing sample mix-ups and contamination issues arising from the multi-step NGS experimental workflow.

Perfect probe design relies on superior algorithmic performance. Built upon 20 years of accumulated expertise, Roche’s probe design technology delivers an unprecedented user experience. It rapidly identifies optimal design solutions, thereby eliminating the time and cost associated with iterative optimization. Its targeted probe placement strategy for regions of interest ensures robust coverage even in complex genomic areas. The algorithm balances uniformity and specificity, maintaining high on-target rates without compromising uniformity.

Empowered by both classic design algorithms and enhanced probe manufacturing processes, targeted sequencing achieves more accurate variant detection and effectively reduces sequencing costs.

It is understood that the HyperDesign intelligent online design tool (https://www.hyperdesign.com/), which supports panel design matching, will be upgraded simultaneously, featuring a more user-friendly interface and enhanced functionality.With HyperDesign, users can flexibly customize probes according to experimental requirements., allowing users to upload sequences in the "User-Designed" mode for rapid design solutions, or to receive one-on-one expert assistance throughout the probe design process in the "Expert-Assisted Design" mode. The well-validated design algorithms and robust cloud computing capabilities enableProbe Design Strategy with High Uniformity and High CoverageReadily available.

Targeted sequencing is a research strategy that involves enriching genomic regions of interest using capture kits prior to sequencing. In practical applications, researchers can design experiments based on existing targeted sequencing protocols, such as whole-exome sequencing, or develop specialized capture probes tailored to specific needs. A comprehensive product portfolio should, on one hand, include mature, stable, and widely recognized off-the-shelf products, and on the other hand, meet the personalized customization requirements of diverse users.

Leveraging its extensive experience in the field of targeted sequencing, Roche has launched a comprehensive product portfolio that delivers a convenient, efficient, and stable user experience at every step of the targeted sequencing workflow. This portfolio includes the online probe design tool HyperDesign (www.hyperdesign.com), the KAPA HyperPrep Library Prep Kit and KAPA HyperPlus Library Prep Kit for library preparation, as well as dual-index unique adapters, purification magnetic beads, and capture probes. The capture probes encompass the KAPA HyperExome whole-exome probes, KAPA HyperChoice human custom probes, and KAPA HyperExplore non-human species custom probes. Roche’s HyperCap Workflow v3.0 provides a simple and efficient integrated workflow for users seeking to establish their own capture sequencing technology platforms and workflows. It reduces hands-on time for manual laboratory platforms while remaining compatible with the rapidly evolving landscape of automated laboratory systems. This comprehensive product ecosystem helps users effectively reduce costs associated with communication, product selection, and workflow adaptation. On a broader scale, it also facilitates the widespread adoption of sequencing technologies and the rapid accumulation of genomic big data.

Roche’s next-generation targeted sequencing portfolio is built upon its years of deep expertise in the field, maintaining Roche’s consistently high standards in key performance indicators such as capture uniformity, product stability, and data quality. In practical application, targeted sequencing is made more accessible and user-friendly through comprehensive end-to-end product coverage, a streamlined and efficient integrated workflow, and intelligent online probe design. Compatibility with automated processes and sample tracking via SNPs demonstrate Roche’s profound understanding of development trends in the high-throughput sequencing industry, laying a solid foundation for building ecosystems within specialized sectors. We anticipate that these innovations will be widely adopted in clinical research, advancing targeted sequencing technologies to uncover further mysteries of life.